Short Interest in Adlai Nortye Ltd. (NASDAQ:ANL) Grows By 112.5%

Adlai Nortye Ltd. (NASDAQ:ANL) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 6,800 shares, a growth of 112.5% from the December 15th total of 3,200 shares. Based on an average daily volume of 16,400 shares, the short-interest ratio is presently 0.4 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price target on shares of Adlai Nortye in a research report on Monday, November 11th.

Adlai Nortye Trading Up 5.0 %

NASDAQ:ANL traded up $0.10 during midday trading on Wednesday, reaching $2.11. 1,186 shares of the stock traded hands, compared to its average volume of 21,942. Adlai Nortye has a 12-month low of $1.85 and a 12-month high of $17.48. The business has a 50-day moving average of $2.39 and a two-hundred day moving average of $2.57.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.